ESPAD Survey: Vaping Prevalent among European Students

Sep.01.2022
ESPAD Survey: Vaping Prevalent among European Students
The ESPAD project investigates alcohol, tobacco, and drug use among 15-16 year old students in 35 European countries.

The European School Survey Project on Alcohol and Other Drugs (ESPAD) is the largest survey of alcohol, tobacco, and illegal drug use among 15-16 year old students in 35 European countries. It is coordinated by the Institute of Clinical Physiology of the National Research Council of Italy (CNR-Ifc). Using standardized methods since 1999, this survey is able to assess changes in young people's habits and has recently garnered interest from the World Health Organization.


Data shows that traditional tobacco cigarette use is declining among adolescents, possibly due to prevention and comparison policies implemented in many countries. However, concerning data about electronic cigarette use has emerged as a worrying trend. In response, the epidemiology and health services research department of CNR-Ifc conducted a study titled "Electronic Cigarette Use and Conventional Smoking Among European Students: Results From the 2019 ESPAD Survey," published in the journal Addiction, to analyze how tobacco control policies impact these habits.


In 2019, a study of approximately 100,000 ESPAD students found that 40.6% had tried traditional cigarettes at least once, with 19.3% currently being smokers. The percentage of smokers varied from 5.1% in Iceland to 32.4% in Italy. On the other hand, 37.8% of students reported trying e-cigarettes, with 12.4% currently using them (13.4% in Italy). According to the study's author, Sonia Cerrai, it can be assumed that young people's attitudes towards new smoking habits will continue to grow, due to the ease of access and perception of low risk.


In the ten countries analyzed, the use of electronic cigarettes has surpassed traditional smoking," stated Cerrai. "While electronic cigarettes may not necessarily contain nicotine, these tech products that are highly attractive to young people and very young individuals are frequently used in conjunction with traditional cigarettes, with usage ranging from 2% in Cyprus to 15% in Monaco (8.9% in Italy) within the sample.


However, implementing tobacco control policies by the government can also contribute to preventing smoking. "In this analysis, we used the Tobacco Control Scale index, which scores policies based on the measures taken," explained Cerrai. "We also considered some specific factors in our analysis: price increases showed a clear association with decreased use of two smoking methods. More spending on information campaigns and cessation programs only correlated with traditional smoking, while measures to prohibit the promotion and advertising of electronic devices were stricter.


According to researchers, the marketing for new devices emphasizes safety by reducing the risks associated with tobacco smoke exposure. However, this complete change in consumption patterns could lead to distractions for young people, who are also familiar with prevention initiatives and programs implemented in the past 20 years.


Statement: 1. The content of this article is compiled from third-party information, provided solely for industry exchange and learning purposes. 2. This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity and accuracy of the article's content. The compilation of this article is only for industry exchange and research purposes. 3. Due to limitations in the compilation process, the compiled article may not fully match the original text. Please refer to the original text for accuracy. 4. 2FIRSTS fully aligns with the Chinese government on any statements and positions related to domestic, Hong Kong, Macau, Taiwan, and foreign issues. 5. Copyright for compiled information belongs to the original media and author. Please contact us for removal if there is any infringement.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11
U.S. Ninth Circuit Upholds FDA Denial of MH Global’s Flavored Vape PMTA Applications
U.S. Ninth Circuit Upholds FDA Denial of MH Global’s Flavored Vape PMTA Applications
The U.S. Court of Appeals for the Ninth Circuit upheld the FDA’s denial of MH Global LLC’s applications to market flavored electronic nicotine delivery systems (ENDS). The court ruled that FDA’s comparative-efficacy framework, which requires applicants to show that flavored products provide greater cessation or switching benefits than tobacco-flavored alternatives, is consistent with the Tobacco Control Act’s “appropriate for the protection of the public health” standard. The court also found that FDA was not required to establish the framework through notice-and-comment rulemaking.
Aug.26
From Nicotine Pouches to Soft Candy Forms: China Tobacco Hubei explores adjustable-release oral nicotine products
From Nicotine Pouches to Soft Candy Forms: China Tobacco Hubei explores adjustable-release oral nicotine products
China-based China Tobacco Hubei Industrial Co., Ltd. has filed a patent application covering an oral nicotine product and its preparation method. The patent proposes a soft candy-shaped oral nicotine product containing nicotine ingredients, gelling agents, sweeteners and alkaline pH regulators. Through formulation adjustments and homogeneous or dual-layer structures, the technology aims to achieve different nicotine release profiles. The filing reflects exploration of new oral nicotine product formats and controlled nicotine delivery approaches.
Aug.06
UK Directors Banned After 352,688 Vapes Imported From China Were Misdeclared as Medical Nebulizers in £15 Million Tax Case
UK Directors Banned After 352,688 Vapes Imported From China Were Misdeclared as Medical Nebulizers in £15 Million Tax Case
The UK Insolvency Service said YSK Enterprises imported large quantities of vapes from China in 2023, with a shipment addressed to the company declared as medical nebulizers before Border Force found 352,688 vaping products. HMRC calculated nearly £15 million ($20.3 million) in unpaid VAT and customs duty, alongside about £437,000 in corporation tax. Two directors were disqualified for nine years. The case predates the UK's Vaping Products Duty, which will introduce vape-specific excise and duty-stamp requirements from October 2026.
Regulations
Sep.11
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Science | International Experts Propose a New Smoking Cessation Pathway, Citing Higher Quit Rates With E-Cigarettes Than Nicotine Replacement Therapy
Science | International Experts Propose a New Smoking Cessation Pathway, Citing Higher Quit Rates With E-Cigarettes Than Nicotine Replacement Therapy
A new expert paper in JAMA urges U.S. clinicians to include nicotine e-cigarettes in smoking-cessation discussions, citing higher quit rates than nicotine replacement therapy. It also stresses that products must deliver enough nicotine to replace cigarettes, dual use should be brief, and complete switching is the goal. 2Firsts argues the recommendations matter beyond clinics: public-health professionals should reassess relative risk, regulators should preserve sufficient product appeal for adult smokers, and manufacturers should focus on helping users quit cigarettes more sustainably.
SCIENCE
Aug.03 by 2Firsts Perspectives